GlassScriptPhysician profile
Jad Al Danaf
NPI 1215342720
$9,848.29
in general payments reported to CMS, 2019-2025
15 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $4,546 · 2022: $461 · 2023: $808 · 2024: $2,052 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,091 · Travel and Lodging: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,091.24 |
| Travel and Lodging | $398.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,216.93 | 2019-2025 | Cardiomems, Aveir |
| Boston Scientific Corporation | $1,593.59 | 2022-2025 | Avvigo Guidance System, General - Balloon Catheters, Crossboss |
| Shockwave Medical, INC | $1,349.99 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $846.34 | 2019-2025 | Impella |
| Medtronic, INC. | $517.47 | 2022-2025 | Micra, Onyx Frontier, Cobalt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $61.85 | 2023-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $39.29 | 2023-2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $38.70 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $35.13 | 2023-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.37 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $29.59 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $28.15 | 2024 | |
| Biotronik INC. | $26.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.31 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $15.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jad Al Danaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.